Alexion Pharmaceuticals Inc., of Cheshire, Conn., said net product sales of Soliris (eculizumab) grew to $636 million in the second quarter, a 24 percent increase, compared to $512.5 million for the same period in 2014, despite currency headwinds. Non-GAAP diluted earnings per share for the second quarter of 2015 were $1.44, compared to $1.12 in the second quarter of 2014. On a GAAP basis, diluted EPS for the second quarter of 2015 was 83 cents per share, impacted by $40.1 million, or 20 cents per share.